PL2155683T3 - Pochodne pirydonu jako inhibitory p38α MAPK - Google Patents

Pochodne pirydonu jako inhibitory p38α MAPK

Info

Publication number
PL2155683T3
PL2155683T3 PL08752572T PL08752572T PL2155683T3 PL 2155683 T3 PL2155683 T3 PL 2155683T3 PL 08752572 T PL08752572 T PL 08752572T PL 08752572 T PL08752572 T PL 08752572T PL 2155683 T3 PL2155683 T3 PL 2155683T3
Authority
PL
Poland
Prior art keywords
mapk inhibitors
pyridone derivatives
pyridone
derivatives
mapk
Prior art date
Application number
PL08752572T
Other languages
English (en)
Inventor
Chiyoshi Kasahara
Hitoshi Yamazaki
Original Assignee
Astellas Pharma Inc
Wakunaga Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Wakunaga Pharma Co Ltd filed Critical Astellas Pharma Inc
Publication of PL2155683T3 publication Critical patent/PL2155683T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL08752572T 2007-05-03 2008-05-02 Pochodne pirydonu jako inhibitory p38α MAPK PL2155683T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91584507P 2007-05-03 2007-05-03
EP08752572A EP2155683B8 (en) 2007-05-03 2008-05-02 Pyridone derivatives as p38a mapk inhibitors
PCT/JP2008/058689 WO2008140066A2 (en) 2007-05-03 2008-05-02 Pyridone derivatives as p38a mapk inhibitors

Publications (1)

Publication Number Publication Date
PL2155683T3 true PL2155683T3 (pl) 2011-08-31

Family

ID=39865639

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08752572T PL2155683T3 (pl) 2007-05-03 2008-05-02 Pochodne pirydonu jako inhibitory p38α MAPK

Country Status (15)

Country Link
US (1) US8173684B2 (pl)
EP (1) EP2155683B8 (pl)
JP (1) JP2010526026A (pl)
KR (1) KR20100016563A (pl)
CN (1) CN101675034A (pl)
AR (1) AR066421A1 (pl)
AT (1) ATE502013T1 (pl)
CA (1) CA2686091A1 (pl)
DE (1) DE602008005581D1 (pl)
ES (1) ES2363109T3 (pl)
MX (1) MX2009011769A (pl)
PL (1) PL2155683T3 (pl)
PT (1) PT2155683E (pl)
TW (1) TW200904421A (pl)
WO (1) WO2008140066A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン, インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
PL2589592T3 (pl) 2010-06-30 2019-03-29 Fujifilm Corporation Nowe pochodne nikotynamidu lub ich sole
CN103221395A (zh) * 2010-11-23 2013-07-24 先正达参股股份有限公司 杀虫化合物
RU2576623C2 (ru) 2011-12-28 2016-03-10 Фуджифилм Корпорэйшн Новое производное никотинамида или его соль
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CN104961803B (zh) * 2015-07-08 2017-11-28 中国人民解放军军事医学科学院基础医学研究所 一种治疗心肌缺血再灌注损伤的多肽药物
CN104961804B (zh) * 2015-07-08 2017-12-01 中国人民解放军军事医学科学院基础医学研究所 p38α拮抗肽突变体及其应用
EP3474835B1 (en) * 2016-06-23 2023-07-05 University of Maryland, Baltimore Non-catalytic substrate-selective p38 -specific mapk inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN107033134B (zh) * 2017-05-03 2020-02-21 贵州大学 含吡啶盐和1,3,4-噁二唑基的双酰胺类化合物及其制备方法及应用
CA3122371A1 (en) 2018-12-07 2020-06-11 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
WO2021064186A1 (en) * 2019-10-04 2021-04-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel pyridin-2(1h)one derivatives, their preparation and their use for the treatment of pain
US11286260B2 (en) 2020-05-18 2022-03-29 Gen1E Lifesciences Inc. P38α mitogen-activated protein kinase inhibitors
AU2021370893B2 (en) 2020-10-29 2024-03-07 Gen1E Lifesciences Inc. Crystalline 5-(dimethylamino) -n- (4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate
IL306101A (en) 2021-03-23 2023-11-01 Gen1E Lifesciences Inc Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
ATE542817T1 (de) 2004-11-10 2012-02-15 Ono Pharmaceutical Co Stickstoffhaltige heterocyclische verbindung und deren pharmazeutische verwendung
RS53599B1 (sr) 2005-05-10 2015-02-27 Intermune, Inc. Piridon derivati za modulaciju stresom aktiviranog sistema proteinskih kinaza
US20090042856A1 (en) 2005-09-01 2009-02-12 Astellas Pharma Inc Pyridazinone derivatives used for the treatment of pain

Also Published As

Publication number Publication date
US20100063098A1 (en) 2010-03-11
ATE502013T1 (de) 2011-04-15
WO2008140066A2 (en) 2008-11-20
JP2010526026A (ja) 2010-07-29
ES2363109T3 (es) 2011-07-20
MX2009011769A (es) 2009-11-13
CN101675034A (zh) 2010-03-17
EP2155683B8 (en) 2011-09-21
EP2155683B1 (en) 2011-03-16
EP2155683A2 (en) 2010-02-24
CA2686091A1 (en) 2008-11-20
WO2008140066A3 (en) 2008-12-31
TW200904421A (en) 2009-02-01
AR066421A1 (es) 2009-08-19
DE602008005581D1 (de) 2011-04-28
PT2155683E (pt) 2011-04-11
KR20100016563A (ko) 2010-02-12
US8173684B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
PL2155683T3 (pl) Pochodne pirydonu jako inhibitory p38α MAPK
ZA200906170B (en) Quinoline derivatives as fungicides
IL211291A0 (en) Picolinamide derivatives as kinase inhibitors
EP2154130A4 (en) pyridone
EP2211615A4 (en) PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
IL202018A0 (en) Quinoline derivatives as pi3 kinase inhibitors
IL197393A0 (en) Pyridin-4-yl derivatives as immunomodulating agents
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ZA201007919B (en) Phenyl or pyridinyl substituted indazoles derivatives
PL2086939T3 (pl) Pirydynokarboksyamidy jako inhibitory 11-beta-hsd1
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
PL2078001T3 (pl) Pochodne diazepano-acetamidowe jako selektywne inhibitory 11-hsd1
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL207972A0 (en) Pyridin-2-yl derivatives as immunomodulating agents
EP2131858A4 (en) P38 INHIBITORS
EP2301922A4 (en) pyridone
EP2285778A4 (en) NIKOTINAMIDDERIVATE
TWI369343B (en) 4-trimethylammonio-butyrates as cpt2 inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
HK1153478A (en) Phenyl or pyridinyl substituted indazoles derivatives
ZA200708877B (en) Dihydropyridine derivatives
GB0716462D0 (en) Pyridine derivatives